Avacopan’s potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis
Modern Rheumatology Case Reports · 08.07.2024 · 8 (2) · 314-317
DOI: 10.1093/mrcr/rxae016 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, online erschienen am 29.03.2024. Verfasst von Tomoki Taniguchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Peroxidase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Avacopan, an orally administered C5a receptor antagonist, is effective in microscopic polyangiitis via the inhibition of neutrophil priming induced by C5a. However, the exact effect of avacopan on the production of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) is yet to be clearly established. This report presents a microscopic polyangiitis patient without major organ damage where high levels of MPO-ANCA persisted with high-dose steroid therapy and azathioprine, but the addition of avacopan led to a reduction in MPO-ANCA titres. The present case implies that avacopan-mediated inhibition of C5a may lead to a reduction in MPO-ANCA levels, thereby potentially ameliorating the pathophysiology of ANCA-associated vasculitis. Nevertheless, the impact of avacopan on MPO-ANCA production cannot be asserted solely based on this report; therefore, further examination is necessary through subgroup analysis using data from larger-scale studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Tomoki Taniguchi, Ryosuke Hiwa, Mirei Shirakashi, Hideaki Tsuji, Ran Nakashima, Hajime Yoshifuji
Zitieren
APA
Taniguchi, T., Hiwa, R., Shoji, M., Yamaguchi, E., Shirakashi, M., Onizawa, H., Tsuji, H., Kitagori, K., Nakashima, R., Akizuki, S., Onishi, A., Yoshifuji, H., Tanaka, M., & Morinobu, A. (2024). Avacopan’s potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis. Modern Rheumatology Case Reports, 8(2), 314-317. https://doi.org/10.1093/mrcr/rxae016
Vancouver
Taniguchi T, Hiwa R, Shoji M, Yamaguchi E, Shirakashi M, Onizawa H, et al. Avacopan’s potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis. Modern Rheumatology Case Reports. 2024;8(2):314-317. doi:10.1093/mrcr/rxae016
BibTeX
@article{Taniguchi2024,
author = {Taniguchi, Tomoki and Hiwa, Ryosuke and Shoji, Mikihito and Yamaguchi, Eriho and Shirakashi, Mirei and Onizawa, Hideo and Tsuji, Hideaki and Kitagori, Koji and Nakashima, Ran and Akizuki, Shuji and Onishi, Akira and Yoshifuji, Hajime and Tanaka, Masao and Morinobu, Akio},
title = {Avacopan’s potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis},
journal = {Modern Rheumatology Case Reports},
year = {2024},
volume = {8},
number = {2},
pages = {314--317},
doi = {10.1093/mrcr/rxae016}
}
EUVIMED